Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment. The partnership will leverage OBT's OGAP-Verify discovery ...

Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment. The partnership will leverage OBT's OGAP-Verify discovery ...

Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based therapeutics for cancer. The multi-year collaboration combines Roche’s drug ...

Roche has secured its third antibody-drug conjugate pact of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics. The agreement will also see U.K.-based ...

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody drug conjugate (ADC)-based therapies, announced a multi-year collaboration with ...

Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with Roche on the hunt for new antibody therapeutics for cancer in a deal ...

Oxford Biotherapeutics Ltd. is partnering with Roche AG to expand the current field of tumor antigens that can be drugged with antibodies, as part of a potential $1 billion-plus agreement. The ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...